Lidocaine/hydrocortisone - Citius Pharmaceuticals

Drug Profile

Lidocaine/hydrocortisone - Citius Pharmaceuticals

Alternative Names: Hydro-Lido; Hydrocortisone/lidocaine - Citius Pharmaceuticals

Latest Information Update: 28 Jul 2016

Price : $50

At a glance

  • Originator Citius Pharmaceuticals LLC
  • Developer Citius Pharmaceuticals Inc
  • Class Acetanilides; Anti-inflammatories; Antiallergics; Class Ib antiarrhythmics; Glucocorticoids; Local anaesthetics; Pregnenediones
  • Mechanism of Action Glucocorticoid receptor agonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Haemorrhoids

Most Recent Events

  • 04 Nov 2015 Phase-IIa clinical trials in Haemorrhoids in USA (Topical) before November 2015
  • 01 Sep 2012 Preclinical trials in Haemorrhoids in USA (Topical) before September 2012
  • 01 Sep 2012 Citius Pharmaceuticals files an IND application with the US FDA for Haemorrhoids (Citius Pharmaceuticals, Form 8-K filed in September 2014)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top